<?xml version="1.0" encoding="UTF-8"?>
<p>During lockdown, 15 patients stopped carfilzomib maintenance completely after a median of 15 cycles (range 5–18), six of whom completed &lt; 12 (median seven cycles; range 5–8); 14 carried on uninterrupted and 41 patients restarted after a median treatment pause of 12 weeks (range 8–19·6). These protocol amendments allowed 55 patients who would otherwise have stopped trial treatment to stay on carfilzomib maintenance on the CARDAMON study (Fig 
 <xref rid="bjh17168-fig-0001" ref-type="fig">1</xref>). Of 25 outstanding MRD BM assessments, 20 were delayed by a median of two months (range 1–3), with investigations resuming when restrictions eased in June. As of 5 August 2020, eight of the delayed BM assessments have been performed, while three patients declined. PET‐CT scans were delayed in 6/9 patients, of which two have been performed.
</p>
